VivaGel(R) Demonstrates Efficacy in Bacterial... (promising and indicate that VivaGel(R) i...)

VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis

Date:5/23/2011

promising and indicate that VivaGel(R) is a potentially useful alternative acute treatment for BV that is different from the systemic and topical antibiotic agents that are the current mainstay of treatment."

The study was a double-blind, randomized, placebo controlled, dose ranging Phase 2 study and was conducted at sites in the US under an Investigational New Drug (IND) application with the US FDA. The study enrolled 132 women who were randomized to receive VivaGel(R) (0.5%, 1% or 3% SPL7013), or placebo. The incidence of adverse events, including genitourinary adverse events, was similar across all placebo gel and VivaGel(R) groups. No severe (grade 3) adverse events were observed in the VivaGel(R) groups. Two severe adverse events were observed in the placebo.

Additional details and results from the study are provided in the Appendix to this announcement.

Addressable global market for BV treatment and prevention potentially exceeds $1B

The global market for topical BV treatments alone is estimated at approximately US$350M. Starpharma's modeling suggests the addressable global market for prevention of recurrence of BV is potentially in excess of $1 billion, due to the long term usage associated with such a product.

Trial results support new patent filing which extends VivaGel(R) protection to at least 2032
On the basis of the data from this phase 2 study, Starpharma has filed a new patent application relating to BV that will, once granted, expand and extend patent protection for VivaGel(R) to at least 2032.

Planning underway for Phase 3 trials for VivaGel(R) for BV treatment
Based on the results of this phase 2 study, Starpharma will undertake further discussions with regulatory authorities, with a view to initiating phase 3 registration trials of VivaGel(R) for the treatment of BV in late 2011 or early 2012.

BV prevention trial of VivaGel(R) to commence Q3 2011
As previously announced Sta
'/>"/>

SOURCE Starpharma
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria

Post Your Comments:

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions ... of proprietary clinical grade hypothermic storage and ... and contract aseptic media manufacturer , today announced ... & Regenerative Medicine Congress 2013 this week in ... http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) Dr. Aby J. Mathew, BioLife,s ...

(Date:5/23/2013)... SAN DIEGO and PARIS ... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today ... V asodilator I ndependent S tenosis ... late breaking clinical trial session at EuroPCR 2013. These ...

(Date:5/23/2013)... LAUSANNE , Switzerland ... 23, 2013 Cenix BioScience, ... developer specialized in RNAi-, miRNA- and high content-driven ... biopharmaceutical group of companies with a focus on ... medical needs, including oncology and companion diagnostics, today ...

Breaking Medicine Technology:BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5 Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2 Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3 Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4

[0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress [0] Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 [0] Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers

... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...

... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...

Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4

Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference

(Date:5/23/2013)... (PRWEB) May 23, 2013 Teen birth rates ... according to new data released today by the ... the teen birth rate dropped at least 15% in 48 ... , There were also dramatic declines among all racial/ethnic groups ... , Birth rates declined 40% or more for Hispanic teens ...

(Date:5/23/2013)... To better serve the architecture and ... to announce the release of its new selections ... division products. Provided by Koroseal, a leader in ... and colors represent a sophisticated response to contemporary ... team of Koroseal experts, Modernfold reviewed hundreds of ...

(Date:5/23/2013)... that can cause rapidly progressing, life threatening meningitis and ... we have not known how it attaches to the ... it attaches to the airway to colonise", People can ... symptoms, while some people progress to invasive disease. ... of how the bacterium colonises the airway. Now that ...

(Date:5/23/2013)... to a new market report "Service Delivery Platform (SDP) ... Telecom Application Server; Service Creation Environment; Orchestration Environment] - ... MarketsandMarkets, the SDP Market is expected to reach $6.94 ... 2013 to 2018. , Browse:, , ... , 189 Pages and an in-depth Table ...

(Date:5/23/2013)... May 23, 2013 Verndale, an ... the launch of Current Digital, a business dedicated ... and digital marketing needs. Companies now view content ... business necessity. This can often leave agencies placed ... on preselected software platforms that they may not ...

Breaking Medicine News(10 mins):Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2 Health News:New discovery in fight against deadly meningococcal disease 2 Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2 Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3 Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2 Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3

[0] New State Teen Birth Data Released; Declines in 48 States from 2007 through 2011 - A Statement from the National Campaign to Prevent Teen and Unplanned Pregnancy [0] Modernfold Debuts New Colors and Patterns for Space Division Products [0] New discovery in fight against deadly meningococcal disease [0] Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets [0] Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies

... HealthDay Reporter , TUESDAY, April 10 (HealthDay News) -- U.S. ... -- a man-made version of the hormone progesterone -- may ... will require new labels. The U.S. Food and Drug ... pills -- which include products such as Bayer,s Yaz or ...

... HealthDay Reporter , TUESDAY, April 10 (HealthDay News) ... heart test -- an electrocardiogram, or EKG -- translate into ... heart attacks, hospitalizations for chest pain or the need for ... For people with major abnormalities in their EKG, the ...

... TUESDAY, April 10 (HealthDay News) -- American youngsters have a long ... childhood obesity rate, a new study shows. The U.S. Department ... the childhood obesity rate to 14.6 percent by 2020, and to ... an average of 64 calories a day. Without this reduction ...

... in low- and middle-income countries, and there is an ... help tackle the disease, states an analysis in CMAJ ... more people than HIV/AIDS, tuberculosis and malaria combined. The ... rise through 2030 of 82% in low- and lower-income ...

... be good for your health, particularly when parental support ... Boston University School of Public Health (BUSPH) researcher Emily ... adults in a representative Massachusetts sample reported receiving positive ... Their incidence of mental health and substance abuse problems ...

... American Society of Pediatric Otolaryngology (ASPO) will hold its ... 2012 Combined Otolaryngology Spring Meetings (COSM) - a joint ... During the ASPO meeting, hundreds of pieces of ... panelists will be presented focusing on children,s ear, nose, ...

Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA EKG Heart Test May Predict Risk in Older Adults Young Americans Need to Cut Calorie Intake: Study Canada should play a role in addressing the global cancer epidemic Supporting LGB children may influence their long-term health, BU study finds Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting

... The TOPCON 3D+ ALE-3700/3700PC/3700CF patternless processing ... to frame, quickly, accurately and with the ... incorporates the 3D+ FR-20 Frame Reader, advanced ... system is available with a polycarbonate feature ...

... Cutting-edge technology enables a fast, precise ... every time. Introducing the TOPCON ALE-X1. The ... a host of improved features and functions. ... both flat and beveled edges, precise three-dimensional ...

...

... TOPscan Dispensers used to only have two choices ... the completed job at a wholesale lab, which ... alternative was to finish the order in house, ... offices required another edger, lens inventory, more space ...

Medicine Products:

TOPCON ALE-3700 patternless lens edger TOPCON ALE-X1 Paternless Lens Edger Topcon PS-9 Manual Blocker Topcon Remote Tracing Software